Overview
- Editors:
-
-
Rainer Spanagel
-
Abteilung für Psychopharmakologie, Universit ät Heidelberg, Mannheim, Germany
-
Karl F. Mann
-
Klinik für Abhängiges Verhalten und Suchtmedizin, Mannheim, Germany
- Complete picture on modern relapse prevention
- Different neurotransmitter/peptide systems involved in relapse behaviour
- New relapse prevention strategies
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (20 chapters)
-
-
-
-
- Henry R. Kranzler, Howard Tennen
Pages 23-39
-
- Dieter Ladewig, Ulrich von Bardeleben
Pages 41-48
-
-
- Charles P. O’Brien, Helen M. Pettinati, David W. Oslin
Pages 59-72
-
- Philippe De Witte, Daniel Bachteler, Rainer Spanagel
Pages 73-83
-
-
- Anh Dzung Lê, Douglas R. Funk
Pages 95-106
-
-
-
-
-
-
- Mauro A.M. Carai, Roberta Agabio, Giovanni Addolorato, Gian L. Gessa, Giancarlo Colombo
Pages 163-170
-
- Giovanni Addolorato, Ludovico Abenavoli, Lorenzo Leggio, Giosuè DeLorenzi, Anna Ferrulli, Fabio Caputo et al.
Pages 171-180
-
- Mauro A.M. Carai, Carla Lobina, Gian Luigi Gessa, Giancarlo Colombo
Pages 181-187
-
- Markus Heilig, Todd E. Thiele
Pages 189-203
-
- Daniel Bachteler, Rainer Spanagel
Pages 205-216
About this book
Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several neurochemical pathways in the brain and furthermore that an imprinted drug and addiction memory may scarcely be extinguished. Hence, the question arises as to whether there ought to be a reasonable hope that pharmacological drugs will be developed that interfere with an addiction memory, and as a result, finally lead to a cure? In this book, leading preclinical and clinical experts in the field of alcohol relapse prevention strive to furnish an answer to this question. None of the researchers or clinicians believes in a magic bullet that will be of help to all alcoholic patients in overcoming this disease. However, there is now convi- ing evidence demonstrating that specific subpopulations of alcoholic patients experience satisfactory benefit from currently available treatments. Today we have two medications for relapse prevention on the market – acamprosate and naltrexone. Although, currently, only a minority of alcoholic patients benefit from these medications, the approval of these compounds may be considered a hallmark in the field of psychopharmacology, even comparable to the era when the first antidepressant compounds were introduced. In recent years we have been witnessing an enormous growth in the science and knowledge regarding the field of relapse prevention.
Reviews
"The book was a delight to read and the editors must be congratulated on bringing together a diverse group of experts to describe both the pre-clinical and clinical aspects of this topical issue. (...) This book will more than fulfil the requirements of a clinician looking for information about the underlying neurobiology of pharmacotherapy."
(Addiction)
Editors and Affiliations
-
Abteilung für Psychopharmakologie, Universit ät Heidelberg, Mannheim, Germany
Rainer Spanagel
-
Klinik für Abhängiges Verhalten und Suchtmedizin, Mannheim, Germany
Karl F. Mann
